Cargando…

The Perilous PPI: Proton Pump Inhibitor as a Cause of Clinically Significant Hypomagnesaemia

Proton pump inhibitors (PPIs) are the mainstay of therapy for all gastric acid related diseases and are commonly used in current clinical practice. Although widely regarded as safe, PPIs have been associated with a variety of adverse effects, including hypomagnesaemia. The postulated mechanism of PP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tai, Yong Ting, Tong, Chin Vong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of the ASEAN Federation of Endocrine Societies 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784231/ https://www.ncbi.nlm.nih.gov/pubmed/33442177 http://dx.doi.org/10.15605/jafes.035.01.18

Ejemplares similares

Hypomagnesaemia associated with long-term use of proton pump inhibitors
por: Toh, James Wei Tatt, et al.
Publicado: (2015)

Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients
por: Douwes, Rianne M., et al.
Publicado: (2019)

Does long-term use of proton pump inhibitors cause hypomagnesaemia in Japanese outpatients?
por: Takeda, Yasuhito, et al.
Publicado: (2015)

A Patient on Long-Term Proton Pump Inhibitors Develops Sudden Seizures and Encephalopathy: An Unusual Presentation of Hypomagnesaemia
por: Gandhi, Nirav Y., et al.
Publicado: (2012)

'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?
por: Atkinson, Nathan S. S., et al.
Publicado: (2015)

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
por: Sharma, Rakesh K, et al.
Publicado: (2010)

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
por: Kenngott, S, et al.
Publicado: (2010)

Hypomagnesaemia – One Cause To Remember!
por: Viegas, Ana Filipa, et al.
Publicado: (2022)

PS212. Effects of Proton Pump Inhibitors (PPI) on the Serum Concentrations of Venlafaxine
por: Paulzen, Michael, et al.
Publicado: (2016)

Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity
por: Burmeister, Melissa A., et al.
Publicado: (2023)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Dietary Inulin Fibers Prevent Proton-Pump Inhibitor (PPI)-Induced Hypocalcemia in Mice
por: Hess, Mark W., et al.
Publicado: (2015)

Hypomagnesaemia and Magnesium Deficiency
por: Sutton, R. A. L.
Publicado: (1968)

Association of Proton Pump Inhibitor (PPI) Use with Energy Intake, Physical Activity, and Weight Gain
por: Czwornog, Jennifer L., et al.
Publicado: (2015)

Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease
por: Arj, Abbas, et al.
Publicado: (2022)

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics
por: Claverie-Martin, Felix
Publicado: (2015)

Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy
por: Nakamura, Kazuhiko, et al.
Publicado: (2016)

Case Report: Investigation and molecular genetic diagnosis of familial hypomagnesaemia
por: Willows, Jamie, et al.
Publicado: (2019)

Hydrochlorothiazide: Refractory hypokalaemia and hypomagnesaemia in an elderly patient: case report
Publicado: (2013)

Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients
por: Lee, Hee Jeong, et al.
Publicado: (2018)

Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial
por: Hojo, Mariko, et al.
Publicado: (2022)

Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients
por: Lee, Hee Jeong, et al.
Publicado: (2018)

Hypomagnesaemia induced recurrent cerebellar ataxia: an interesting case with successful management
por: Kumar, Singh Saraj, et al.
Publicado: (2020)

Severe hypomagnesaemia with tetany following ESHAP protocol
por: Majumdar, Gautam
Publicado: (2002)

Hypomagnesaemia induced hypocalcemia mimicking as acute exacerbation of COPD—Rare cause of a common presentation: A case report
por: Roy, Shankar, et al.
Publicado: (2020)

Two novel mutations of the CLDN16 gene cause familial hypomagnesaemia with hypercalciuria and nephrocalcinosis
por: Hanssen, Oriane, et al.
Publicado: (2014)

Proton pump inhibitors induce hemolytic anemia
por: Al-Nasser, Asayil Nasser, et al.
Publicado: (2019)

Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication
por: Semb, Synne, et al.
Publicado: (2017)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

P029: Regional differences in Clostridium difficile infections (CDI) in relation to fluoroquinolone (FQ) and proton pump inhibitor (PPI) use, Finland, 2008-2011
por: Kanerva, M, et al.
Publicado: (2013)

Hypomagnesaemia As a Mortality Risk Factor in Protein-energy Malnutrition
por: Karakelleoglu, Cahit, et al.
Publicado: (2011)

A novel CLDN16 mutation in a large family with familial hypomagnesaemia with hypercalciuria and nephrocalcinosis
por: Deeb, Asma, et al.
Publicado: (2013)

Can proton pump inhibitors cause intestinal inflammation in children?
por: Kang, Ben
Publicado: (2019)

The perils of antiepileptic toxicity
por: Madan, Arushi, et al.
Publicado: (2020)

Acute interstitial nephritis due to proton pump inhibitors
por: Sampathkumar, K., et al.
Publicado: (2013)

Proton Pump Inhibitor-Induced Remission of Lymphocytic Esophagitis
por: Sloan, Joshua, et al.
Publicado: (2016)

An unusual case of proton pump inhibitor induced hyperchromograninemia
por: Adu-Gyamfi, Kwabena Oware, et al.
Publicado: (2019)

Cyclooxygenase-2 inhibitors: promise or peril?
por: Mengle-Gaw, Laurel J, et al.
Publicado: (2002)

The promise and perils of HDAC inhibitors in neurodegeneration
por: Didonna, Alessandro, et al.
Publicado: (2015)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_49qro2hd23cpj3me5kkc4942d0